icon
0%

Illumina ILMN - News Analyzed: 3,847 - Last Week: 100 - Last Month: 498

⇗ Illumina ILMN Displays Mixed Signals with Acquisitions, Earnings Beats and Sales Declines

Illumina ILMN Displays Mixed Signals with Acquisitions, Earnings Beats and Sales Declines
Retirement Systems of Alabama and New York State Teachers Retirement System bought substantial shares of Illumina, Inc. (NASDAQ:ILMN), while Nisa Investment Advisors LLC reduced their holdings. Illumina's Q2 results surpassed expectations, yet announced lower revenue expectations for 2024. Illumina acquired Fluent BioSciences to expand single-cell analysis and discovery. Indications suggest Illumina's international revenue plays a significant role. Illumina concluded GRIL divestment, upgraded to a buy rating, and appointed Ankur Dhingra as CFO and Jakob Wedel as Chief Strategy and Corporate Development Officer. Despite its promising growth prospects and contribution towards making genomic testing a standard in oncology, Illumina faced a stock decline. Illumina's DRAGEN v4.3 delivers innovative genomic solutions. Yet, facing a biotech funding crunch, Illumina anticipates a decline in full-year sales from the core segment. Activist pressure from Icahn Enterprises is also a significant point. Its Grail spin-off had mixed reactions, on one hand, upgrading the firm's rating and boosting stocks, and on the other warned for significant loss.

Illumina ILMN News Analytics from Fri, 29 Dec 2023 08:00:00 GMT to Sun, 25 Aug 2024 09:03:34 GMT - Rating 5 - Innovation 6 - Information 8 - Rumor -6

The email address you have entered is invalid.